ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1181

Hippo Pathway Effectors Promote and Maintain Myofibroblast Differentiation and Endothelial-to-mesenchymal Transition in Systemic Sclerosis

Feiyang Ma1, Pei-Suen Tsou1, Grace Hile1, John Varga1, J. Michelle Kahlenberg1, Allison Billi1, Johann Gudjonsson1 and Dinesh Khanna2, 1University of Michigan, Ann Arbor, MI, 2Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI

Meeting: ACR Convergence 2022

Keywords: Bioinformatics, Fibroblasts, Dermal, Scleroderma, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Systemic Sclerosis and Related Disorders – Basic Science Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Systemic sclerosis (SSc) is a devastating autoimmune disease characterized by excessive production and accumulation of extracellular matrix molecules leading to fibrosis of skin and other internal organs. However, the mechanisms and the main cellular participants in SSc skin fibrosis remain incompletely understood. Here, we sought to provide a detailed and comprehensive characterization of the cellular and molecular events underlying skin fibrosis in SSc.

Methods: To understand the unbiased cellular composition and cell states of healthy normal skin (NS) and (SSc) skin, we generated single cell suspensions of skin biopsies from 18 NS donors and 22 SSc patients and performed single cell RNA sequencing (scRNA-seq). To localize the major cell types detected by scRNA-seq in SSc skin, we performed spatial sequencing (spatial-seq) on the SSc skin sample using the 10X Visium platform. The R package Seurat was used to analyze and integrate the scRNA-seq and spatial-seq datasets. The R package Monocle was used to perform pseudotime trajectory analysis. CellphoneDB was used to construct ligand-receptor networks among different cell types. Fibroblasts and endothelial cells isolated from dcSSc skin were cultured with TRULI and verteporfin to test the roles of Hippo pathway effectors in myofibroblast differentiation and EndoMT.

Results: We demonstrated a dual source of extracellular matrix deposition in SSc skin from both myofibroblasts and endothelial to mesenchymal transitioning cells (EndoMTs) (Figure 1). Importantly, pseudotime trajectory analysis, which aligns the relationship of fibroblast and endothelial subsets identified a central role of Hippo pathway effectors in promoting and maintaining myofibroblast differentiation and EndoMT (Figure 2). Ligand-receptor analysis revealed that myofibroblasts and EndoMTs act as central communication hubs that drive key pro-fibrotic signaling pathways in SSc (Figure 3). Inhibition of TEAD/YAP interactions, key transcription coactivators in Hippo signaling, reversed pro-fibrotic phenotypes in myofibroblasts and EndoMTs. Together, these data provide comprehensive and detailed characterization of myofibroblast differentiation and EndoMT in SSc skin and identify a novel pathway to target for fibrosis reversal.

Conclusion: Hippo pathway effectors, which regulate cell proliferation, inflammatory, and apoptotic pathways, promote and maintain myofibroblast differentiation and endothelial-to-mesenchymal transition in systemic sclerosis. Modulation of the Hippo pathway should be further studied in SSc.


Disclosures: F. Ma, None; P. Tsou, None; G. Hile, None; J. Varga, Boehringer-Ingelheim; J. Kahlenberg, Q32 Bio, Celgene/Bristol Myers Squibb, Ventus Therapeutics, Rome Therapeutics, Janssen, AstraZeneca, Eli Lilly, GlaxoSmithKline, Bristol Myers Squibb, Avion Pharmaceuticals, Provention Bio, Aurinia Pharmaceuticals, Boehringer Ingelheim; A. Billi, None; J. Gudjonsson, None; D. Khanna, Boehringer Ingelheim, Genentech, Prometheus, Horizon, Chemomab, Talaris, Gesynta, Amgen, Acceleron, Actelion, Bayer, CSL Behring, Paracrine Cell Therapy, Mitsubishi Tanabe, Theraly, Eicos Sciences.

To cite this abstract in AMA style:

Ma F, Tsou P, Hile G, Varga J, Kahlenberg J, Billi A, Gudjonsson J, Khanna D. Hippo Pathway Effectors Promote and Maintain Myofibroblast Differentiation and Endothelial-to-mesenchymal Transition in Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/hippo-pathway-effectors-promote-and-maintain-myofibroblast-differentiation-and-endothelial-to-mesenchymal-transition-in-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hippo-pathway-effectors-promote-and-maintain-myofibroblast-differentiation-and-endothelial-to-mesenchymal-transition-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology